Motzer RJ - Search Results

1

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.

Pignon JC, Jegede O, Shukla SA, Braun DA, Horak CE, Wind-Rotolo M, Ishii Y, Catalano PJ, Grosha J, Flaifel A, Novak JS, Mahoney KM, Freeman GJ, Sharpe AH, Hodi FS, Motzer RJ, Choueiri TK, Wu CJ, Atkins MB, McDermott DF, Signoretti S. Pignon JC, et al. Among authors: motzer rj. Clin Cancer Res. 2019 Apr 1;25(7):2174-2184. doi: 10.1158/1078-0432.CCR-18-3206. Epub 2019 Jan 22. Clin Cancer Res. 2019. PMID: 30670497 Free PMC article. Clinical Trial.

2

Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.

Motzer RJ, Nanus DM, O'Moore P, Scher HI, Bajorin DF, Reuter V, Tong WP, Iversen J, Louison C, Albino AP, et al. Motzer RJ, et al. Cancer Res. 1992 Oct 15;52(20):5775-9. Cancer Res. 1992. PMID: 1394202 Clinical Trial.

3

A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.

Ilson DH, Motzer RJ, Kradin RL, Vogelzang NJ, Bajorin DF, Scher HI, Nanus D, O'Moore P, Marathias K, Bosl GJ. Ilson DH, et al. Among authors: motzer rj. J Clin Oncol. 1992 Jul;10(7):1124-30. doi: 10.1200/JCO.1992.10.7.1124. J Clin Oncol. 1992. PMID: 1607918 Clinical Trial.

4

Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors.

Motzer RJ, Cooper K, Geller NL, Pfister DG, Lin SY, Bajorin D, Scher HI, Herr H, Fair W, Morse M, et al. Motzer RJ, et al. Cancer. 1990 Jun 1;65(11):2465-70. doi: 10.1002/1097-0142(19900601)65:11<2465::aid-cncr2820651112>3.0.co;2-7. Cancer. 1990. PMID: 1692505

5

Phase II trial of Didemnin B in patients with advanced renal cell carcinoma.

Motzer R, Scher H, Bajorin D, Sternberg C, Bosl GJ. Motzer R, et al. Invest New Drugs. 1990 Nov;8(4):391-2. doi: 10.1007/BF00198598. Invest New Drugs. 1990. PMID: 2084073 Clinical Trial.

6

The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors.

Motzer RJ, Cooper K, Geller NL, Bajorin DF, Dmitrovsky E, Herr H, Morse M, Fair W, Sogani P, Russo P, et al. Motzer RJ, et al. Cancer. 1990 Dec 15;66(12):2476-81. doi: 10.1002/1097-0142(19901215)66:12<2476::aid-cncr2820661206>3.0.co;2-d. Cancer. 1990. PMID: 2174300 Clinical Trial.

7

Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors.

Motzer RJ, Bajorin DF, Schwartz LH, Hutter HS, Bosl GJ, Scher HI, Lyn P, Fischer P. Motzer RJ, et al. J Clin Oncol. 1994 Nov;12(11):2277-83. doi: 10.1200/JCO.1994.12.11.2277. J Clin Oncol. 1994. PMID: 7525885 Clinical Trial.

8

Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro.

Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, Vlamis V, Nanus DM. Motzer RJ, et al. J Clin Oncol. 1995 Aug;13(8):1950-7. doi: 10.1200/JCO.1995.13.8.1950. J Clin Oncol. 1995. PMID: 7636535 Clinical Trial.

9

Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.

Motzer RJ, Lyn P, Fischer P, Lianes P, Ngo RL, Cordon-Cardo C, O'Brien JP. Motzer RJ, et al. J Clin Oncol. 1995 Aug;13(8):1958-65. doi: 10.1200/JCO.1995.13.8.1958. J Clin Oncol. 1995. PMID: 7636536 Clinical Trial.

10

Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma.

Law TM, Mencel P, Motzer RJ. Law TM, et al. Among authors: motzer rj. Invest New Drugs. 1994;12(4):323-5. doi: 10.1007/BF00873048. Invest New Drugs. 1994. PMID: 7775134 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

617 results

Search Page